Klebsiella Aerogenes: Infections, Symptoms & Treatment

Klebsiella aerogenes is an opportunistic bacterium that primarily threatens hospitalized patients, especially those with weakened immune systems, invasive devices like catheters, or prolonged antibiotic exposure. It ranks among the more concerning hospital-acquired pathogens because of its ability to develop resistance to multiple antibiotic classes, including last-resort carbapenems. While healthy people rarely encounter it as a threat, the bacterium has been gaining attention in clinical microbiology for its rising drug resistance and its association with worse outcomes than closely related species in bloodstream infections.

A Bacterium With a New Name

If you search older medical literature, you will find this organism listed as Enterobacter aerogenes. In recent years it was formally reclassified into the Klebsiella genus because genetic and physical analysis showed it is more closely related to Klebsiella pneumoniae than to other Enterobacter species.¹ The name change has practical consequences: many hospital microbiology labs still report it under the old name, and some automated identification systems have been slow to update. This creates confusion when clinicians compare treatment guidelines written for “Enterobacter aerogenes” with newer guidelines referencing “Klebsiella aerogenes.” They are the same organism.² Newer diagnostic platforms, including those that use mass spectrometry to identify bacteria by their protein signatures, can now distinguish K. aerogenes from other Klebsiella species reliably.³

Where the Bacterium Lives

K. aerogenes is not confined to hospitals. It is a gram-negative bacterium found widely in the environment, including water, soil, and air.⁴ It also colonizes the human gastrointestinal tract without causing disease in most people. The trouble starts when it reaches a site where it does not belong, such as the urinary tract, bloodstream, lungs, or a surgical wound, typically in someone whose defenses are already compromised.

In agriculture, the organism has been isolated from livestock. Researchers in China identified K. aerogenes strains carrying carbapenem-resistance genes in swine fecal samples, raising the concern that drug-resistant strains can circulate between animals and the broader environment.⁵ It has even been identified in honey bee colonies during episodes of bee dysbiosis.⁶ None of this means you are likely to get a K. aerogenes infection from gardening or eating honey. The clinical danger is overwhelmingly concentrated in healthcare settings, where vulnerable patients and heavy antibiotic use create ideal conditions for opportunistic infection.

Who Gets Infected and How

The typical K. aerogenes patient is already in the hospital for something else. Risk factors include urinary catheters, mechanical ventilation, major surgery, prematurity in newborns, and prolonged courses of broad-spectrum antibiotics. Bloodstream infections with K. aerogenes show a clear skew toward older adults and males, and the genitourinary tract is the most common source.⁷ In children, K. aerogenes bloodstream infections are especially associated with prematurity and urosepsis, and a pediatric study found the organism was independently linked to higher 30-day mortality compared to the closely related Enterobacter cloacae complex.⁸

Community-acquired infections are rarer but not unheard of. A case report from Bangladesh documented a community-acquired urinary tract infection caused by a multidrug-resistant K. aerogenes strain in a patient without recent hospitalization, suggesting that resistant strains are beginning to escape the hospital environment.⁹

Types of Infections and Their Symptoms

K. aerogenes does not cause a single distinctive illness. Instead, it causes the standard array of bacterial infections depending on which body site it invades. The most common is urinary tract infection, which makes sense given the bacterium’s affinity for the genitourinary tract and the fact that catheter use is a major risk factor.¹⁰ Symptoms of a catheter-associated UTI include fever, flank or suprapubic pain, cloudy or foul-smelling urine, and sometimes confusion in elderly patients. Many catheter-associated UTIs, however, produce surprisingly few symptoms early on and are discovered through routine cultures.

Bloodstream infections (bacteremia or sepsis) are the most dangerous presentation. Symptoms typically include high fever, chills, rapid heart rate, low blood pressure, and in severe cases, organ dysfunction. The speed of onset can be alarming, particularly in neonates, where symptoms can appear within days of birth. In one neonatal intensive care unit outbreak, symptoms appeared at an average age of about three and a half days, with a range of three to eight days.¹¹

Respiratory tract infections, including ventilator-associated pneumonia, are another frequent presentation. These bring fever, cough, increased sputum production, and worsening oxygen levels. Less commonly, K. aerogenes can cause surgical site infections, intra-abdominal infections, and, rarely, central nervous system infections like meningitis. Whatever the site, the symptoms are not specific to this organism. Diagnosis depends on laboratory culture, not on recognizing a particular symptom pattern.

Why Resistance Is the Central Problem

What makes K. aerogenes particularly worrisome is not the infections themselves, which look like any gram-negative bacterial infection, but the pace at which the organism acquires resistance. Over the past few decades, strains resistant to multiple drug classes have become common, and truly pandrug-resistant strains, susceptible to nothing in the standard pharmacy, have been reported.¹⁰

The bacterium uses several resistance strategies simultaneously. One of the most clinically significant is an enzyme called AmpC beta-lactamase. This enzyme is encoded on K. aerogenes’ own chromosome, meaning every strain carries the potential for it. Under normal conditions, the enzyme is produced at low levels. But when certain antibiotics, particularly third-generation cephalosporins, are present, the gene can be “switched on” at much higher levels. This is called inducible AmpC expression, and it can transform a strain that initially appears susceptible on a lab test into one that is resistant during treatment.

A second strategy involves the loss or narrowing of porins, which are the channels in the bacterium’s outer membrane that antibiotics use to enter the cell. When these channels mutate, antibiotics have a harder time getting inside. A study tracking how K. aerogenes evolved carbapenem resistance within a single patient found that early strains carried a porin mutation that narrowed the channel by about 15 percent, which on its own was not enough to cause resistance. But later strains acquired a second mutation that completely destroyed the porin. When that total loss of porin function was combined with the inducible AmpC enzyme, the result was full carbapenem resistance, without the bacterium ever acquiring a dedicated carbapenem-destroying enzyme.¹² That synergy between reduced drug entry and enzymatic degradation is a pattern seen across many gram-negative pathogens, but K. aerogenes is especially efficient at deploying both at once.

On top of these intrinsic mechanisms, K. aerogenes readily picks up resistance genes from other bacteria through horizontal gene transfer. A study of carbapenem-resistant K. aerogenes isolates from a hospital in southwestern China found that strains carried a staggering array of acquired resistance genes: nearly all had quinolone-resistance genes, about two-thirds carried AmpC genes, over a third had extended-spectrum beta-lactamase (ESBL) genes, and a quarter carried aminoglycoside-resistance genes. Active efflux pumps, which physically pump antibiotics out of the cell, were functional in roughly 70 percent of these carbapenem-resistant strains.¹³ Some strains even carried genes for dedicated carbapenem-destroying enzymes like NDM-1 or KPC-2, the same resistance mechanisms that have made carbapenem-resistant K. pneumoniae a global emergency. Porin loss, which reduces drug entry, was also documented among these isolates.¹³

Treatment Options

Choosing the right antibiotic for K. aerogenes requires up-to-date susceptibility testing, because the organism’s resistance profile varies enormously by strain and by hospital. There is no single default drug the way there might be for a less resistant pathogen. That said, a few treatment patterns emerge from the clinical literature.

For susceptible strains causing less severe infections, third-generation cephalosporins like ceftriaxone have been used as definitive therapy. A Japanese study comparing outcomes between patients treated with third-generation cephalosporins and those treated with other drugs for K. aerogenes or Enterobacter bacteremia found no significant difference in 30-day mortality, recurrence, or need to escalate treatment.¹⁴ This is somewhat reassuring, but it comes with a major caveat: these results apply to strains confirmed as susceptible, and the risk of inducible AmpC resistance emerging during treatment remains a concern. Some infectious disease specialists prefer to avoid third-generation cephalosporins entirely for K. aerogenes bacteremia because of that risk, even when initial testing shows susceptibility.

Cefepime, a fourth-generation cephalosporin, is often considered a better choice because it is more stable against AmpC enzymes. Laboratory data show that cefepime can substantially reduce bacterial counts even against high-inoculum K. aerogenes.¹⁵ A retrospective study of critically ill patients infected with ESBL-producing strains found that high-dose cefepime produced clinical improvement rates and mortality rates comparable to carbapenems.¹⁶ In that study, about 62 percent of cefepime-treated patients improved clinically, compared with 70 percent of those on a carbapenem, a difference that was not statistically meaningful.

Carbapenems, such as meropenem and imipenem, remain the heaviest conventional weapons against multidrug-resistant K. aerogenes. They are typically reserved for severe infections or strains resistant to other options, because overuse accelerates resistance. For carbapenem-resistant strains, newer agents like ceftazidime-avibactam have shown promise. Avibactam is a beta-lactamase inhibitor that can neutralize some of the enzymes K. aerogenes uses to destroy antibiotics, restoring the activity of the partnered ceftazidime.¹⁷ Other combination regimens and newer drugs are under investigation, but for now, susceptibility testing on a case-by-case basis remains the only reliable guide.

Outcomes in Bloodstream Infections

When K. aerogenes enters the bloodstream, outcomes tend to be worse than you might expect from a bacterium that was long grouped with the relatively familiar Enterobacter species. A study comparing K. aerogenes and Enterobacter cloacae complex bloodstream infections found that poor clinical outcomes, defined as death before discharge, recurrent bloodstream infection, or major complications, occurred in about 70 percent of K. aerogenes patients versus 40 percent of those with the Enterobacter cloacae complex. After adjusting for other factors, K. aerogenes bloodstream infection was associated with roughly triple the odds of a poor outcome.²

That finding, however, does not mean K. aerogenes is inherently more lethal. A larger population-level study examining thousands of bloodstream infections found that while the patient profiles differed, there were no significant differences in 30-day mortality or hospital length of stay between K. aerogenes and E. cloacae infections once other variables were considered.⁷ The discrepancy between these findings likely reflects differences in how “poor outcome” was defined and the populations studied. The practical takeaway is that K. aerogenes bloodstream infection is serious, associated with complications and recurrences, and should not be dismissed as a mild pathogen just because it was historically lumped in with the Enterobacter group.

Hospital Outbreaks and How They Happen

K. aerogenes has caused well-documented outbreaks in healthcare facilities, and the transmission routes are sometimes surprising. One neonatal intensive care unit outbreak involving 13 newborns was traced to the rubber tubing of a foot-operated suction machine. Seven of the affected infants were premature. The outbreak was controlled only after the unit was temporarily closed, fumigated, and reopened with strict hand-hygiene and cohort-nursing protocols.¹¹

An even more unusual outbreak occurred in a neurosurgical department, where K. aerogenes infections were eventually linked to contaminated shampoo equipment used by an outsourced barber service for preoperative hair shaving. Genetic fingerprinting showed that most patient isolates shared the same clonal strain, and that strain was recovered from the shampoo carts. After the barber service was discontinued and the equipment replaced, no new cases appeared.¹⁸ These examples highlight that the bacterium can lurk in equipment and surfaces that infection-control programs might not routinely scrutinize, especially when services are contracted to outside vendors.

Another outbreak, in a neonatal intensive care unit in Austria, was caused by a K. aerogenes strain that produced yersiniabactin, an iron-scavenging molecule typically associated with highly pathogenic bacteria. Yersiniabactin helps the bacterium steal iron from its host, a nutrient essential for bacterial growth. Genetic sequencing confirmed the outbreak strain carried the gene cluster for this virulence factor, and lab testing confirmed the bacteria were actively producing it.¹⁹ The presence of yersiniabactin in an outbreak strain is a reminder that K. aerogenes is not just passively opportunistic; some strains carry real virulence hardware.

Biofilm and Survival on Surfaces

Part of what makes K. aerogenes difficult to eradicate from hospital environments is its ability to form biofilms, communities of bacteria encased in a self-produced matrix that adheres to surfaces. Research on K. aerogenes attachment behavior shows that the bacterium begins adhering to surfaces almost immediately after contact and adjusts its attachment strategy based on the surface properties and the space available.²⁰ The bacterium also releases extracellular DNA, which plays a role in how it interacts with surfaces. Biofilm-embedded bacteria are inherently more resistant to antibiotics and disinfectants than free-floating cells, which is one reason contaminated hospital equipment can remain a source of infection even after routine cleaning. Breaking up biofilms requires more aggressive decontamination strategies than simply wiping a surface down.

K. aerogenes in Animals and the Environment

The discovery of carbapenem-resistance genes in K. aerogenes strains isolated from swine in China is not an isolated curiosity. It fits a broader pattern in which drug-resistant bacteria circulate between humans, livestock, and the environment. Farms that use antibiotics heavily can serve as reservoirs for resistant strains, and bacteria shed in animal waste can enter soil and waterways.⁵ K. aerogenes has also been isolated from agricultural soil far from any hospital, underscoring that this organism is a natural environmental resident, not solely a product of the healthcare setting.⁴ Whether environmental strains pose a direct infection risk to healthy people remains uncertain, but they can exchange resistance genes with strains that do infect humans, contributing to the slow creep of drug resistance outside hospital walls.